US health regulators make it easier to approve new Alzheimer's diagnostic tests

US health regulators just reclassified a new type of Alzheimer's test. This moves the test from the highest regulatory hurdle to a lower one. This means new tests can reach patients faster, with fewer studies required for approval.

For years, getting a new medical device approved in the US meant navigating a complex, expensive process. This reclassification sets a precedent, showing that regulators can create a faster path for certain innovative diagnostic tools. It could unlock new investment in early detection methods for diseases like Alzheimer's, where early diagnosis is critical but often difficult.